<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="14216"><DrugName>siplizumab</DrugName><DrugNamesKey><Name id="42751068">siplizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>MEDI-507</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>siplizumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>AlloMune component II, Biotransplant</Value></Name></DrugSynonyms><CompanyOriginator id="21279">Universite Catholique de Louvain</CompanyOriginator><CompaniesPrimary><Company id="1158077">ITB-MED AB</Company></CompaniesPrimary><CompaniesSecondary><Company id="14847">BioTransplant Inc</Company><Company id="18008">MedImmune LLC</Company><Company id="21279">Universite Catholique de Louvain</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14216" type="Drug"><TargetEntity id="250466" type="siDrug">Siplizumab</TargetEntity></SourceEntity><SourceEntity id="1158077" type="Company"><TargetEntity id="5059973142" type="organizationId">ITB Med AB (publ)</TargetEntity></SourceEntity><SourceEntity id="14847" type="Company"><TargetEntity id="4295905730" type="organizationId">Biotransplant Inc</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="21279" type="Company"><TargetEntity id="5000691790" type="organizationId">Universite Catholique De Louvain</TargetEntity></SourceEntity><SourceEntity id="1781" type="ciIndication"><TargetEntity id="10037162" type="MEDDRA"></TargetEntity><TargetEntity id="D015535" type="MeSH"></TargetEntity><TargetEntity id="-689721545" type="omicsDisease"></TargetEntity><TargetEntity id="724" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"></TargetEntity><TargetEntity id="D007938" type="MeSH"></TargetEntity><TargetEntity id="-609576380" type="omicsDisease"></TargetEntity><TargetEntity id="683" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3004" type="ciIndication"><TargetEntity id="10061890" type="MEDDRA"></TargetEntity><TargetEntity id="D016377" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="36" type="ciIndication"><TargetEntity id="10061664" type="MEDDRA"></TargetEntity><TargetEntity id="D001327" type="MeSH"></TargetEntity><TargetEntity id="-2072222280" type="omicsDisease"></TargetEntity><TargetEntity id="729" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="515" type="ciIndication"><TargetEntity id="10044439" type="MEDDRA"></TargetEntity><TargetEntity id="D006084" type="MeSH"></TargetEntity><TargetEntity id="1133" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"></TargetEntity><TargetEntity id="10018651" type="MEDDRA"></TargetEntity><TargetEntity id="D006086" type="MeSH"></TargetEntity><TargetEntity id="39812" type="ORPHANET"></TargetEntity><TargetEntity id="-1437372564" type="omicsDisease"></TargetEntity><TargetEntity id="1129" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="5019" type="Action"><TargetEntity id="1568" type="Mechanism">Anti-CD2</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3004">Organ transplantation</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1781">Psoriatic arthritis</Indication><Indication id="199">Leukemia</Indication><Indication id="203">Lymphoma</Indication><Indication id="281">Psoriasis</Indication><Indication id="36">Autoimmune disease</Indication><Indication id="515">Transplant rejection</Indication><Indication id="616">Graft versus host disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="1596">Immunomodulator</Action><Action id="15184">Systemic antipsoriatic product</Action><Action id="2953">Anti-inflammatory</Action><Action id="55685">Anticancer monoclonal antibody</Action><Action id="5019">Lymphocyte function antigen-3 receptor antagonist</Action></ActionsSecondary><Technologies><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-11-16T09:34:01.000Z</LastModificationDate><ChangeDateLast>2018-02-28T00:00:00.000Z</ChangeDateLast><AddedDate>1996-12-19T16:37:40.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1158077" linkType="Company"&gt;ITB-MED&lt;/ulink&gt;, presumably following acquisition of assets relating the drug from &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;, is developing siplizumab, a humanized form of the rat anti-CD2 monoclonal antibody &lt;ulink linkID="8711" linkType="Drug"&gt;BTI-322&lt;/ulink&gt;,  for potential treatment in  solid organ transplantation [&lt;ulink linkID="1965438" linkType="Reference"&gt;1965438&lt;/ulink&gt;]. By September 2017, data from completed phase I/II studies had been published [&lt;ulink linkID="1965438" linkType="Reference"&gt;1965438&lt;/ulink&gt;], [&lt;ulink linkID="1992676" linkType="Reference"&gt;1992676&lt;/ulink&gt;]. In November 2018, development was ongoing [&lt;ulink linkID="2094326" linkType="Reference"&gt;2094326&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt;) was developing siplizumab (MEDI-507) for the potential treatment of hematological cancers, including lymphoma and leukemia [&lt;ulink linkID="487186" linkType="Reference"&gt;487186&lt;/ulink&gt;]. By May 2005, enrollment for phase I trials for the treatment of leukemia and lymphoma was continuing [&lt;ulink linkID="603447" linkType="Reference"&gt;603447&lt;/ulink&gt;], [&lt;ulink linkID="601766" linkType="Reference"&gt;601766&lt;/ulink&gt;]; however, by July 2007, development of the drug had been discontinued [&lt;ulink linkID="816181" linkType="Reference"&gt;816181&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Previously, siplizumab was also under development for immune disorders such as psoriasis, transplant rejection and graft versus host disease (GvHD) [&lt;ulink linkID="228865" linkType="reference"&gt;228865&lt;/ulink&gt;], [&lt;ulink linkID="270316" linkType="reference"&gt;270316&lt;/ulink&gt;]. In September 1998, siplizumab was awarded Orphan Drug status for GvHD when used as part of &lt;ulink linkID="14847" linkType="Company"&gt;BioTransplant&lt;/ulink&gt;'s &lt;ulink linkID="20120" linkType="Drug"&gt;AlloMune&lt;/ulink&gt; Cancer prototype system  [&lt;ulink linkID="299465" linkType="reference"&gt;299465&lt;/ulink&gt;]. By April 2001, siplizumab was in phase I/II trials for the treatment of GvHD, phase II trials for organ rejection and phase II for psoriasis [&lt;ulink linkID="296831" linkType="reference"&gt;296831&lt;/ulink&gt;], [&lt;ulink linkID="403784" linkType="reference"&gt;403784&lt;/ulink&gt;]. In October 2002, preliminary analysis of phase II trials in psoriasis patients showed that siplizumab showed promise in treating psoriasis, and an optimal dose for phase III trials had been identified. However, half of siplizumab-treated patients showed immunogenicity to siplizumab in in vitro tests though these did not seem to clinically affect safety, efficacy and pharmacokinetics of the drug. At that time, MedImmune planned to conduct new phase II retreatment trials in early 2003 to fully investigate this immunogenic response. Phase III pivotal trials were planned for late 2003 [&lt;ulink linkID="467812" linkType="reference"&gt;467812&lt;/ulink&gt;]. In April 2003, MedImmune postponed further clinical trials with siplizumab in psoriasis, pending the outcome of a phase II trial of its monoclonal antibody, &lt;ulink linkID="9563" linkType="Drug"&gt;Vitaxin&lt;/ulink&gt;, in that disorder [&lt;ulink linkID="487214" linkType="Reference"&gt;487214&lt;/ulink&gt;].  By July 2003, phase II trials had been completed [&lt;ulink linkID="498848" linkType="reference"&gt;498848&lt;/ulink&gt;]. However,  by April 2004, the drug was no longer being developed  by MedImmune for GvHD, transplant rejection or psoriasis [&lt;ulink linkID="536761" linkType="Reference"&gt;536761&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In February 2018, the US FDA granted Orphan Drug designation  for siplizumab for the prevention of solid organ transplant rejection [&lt;ulink linkID="2008594" linkType="Reference"&gt;2008594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2017, the COMP recommended granting Orphan designation to ITB-MED for siplizumab for treatment of solid organ transplantation [&lt;ulink linkID="1965438" linkType="Reference"&gt;1965438&lt;/ulink&gt;]; in October 2017, the Orphan designation was granted [&lt;ulink linkID="1987727" linkType="Reference"&gt;1987727&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2006, the COMP of the EMEA gave a positive opinion on Orphan  designation for the drug  for treatment of T-cell and NK-cell neoplasms [&lt;ulink linkID="668386" linkType="Reference"&gt;668386&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;LYMPHOMA AND LEUKEMIA&lt;/subtitle&gt;In May 2005,  clinical data on siplizumab were presented at the 41st ASCO meeting in Orlando, FL. In a dose-escalation phase I trial, siplizumab was evaluated in 13 patients with CD2+ adult T-cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) and large granular lymphocyte leukemia (LGL). Siplizumab (0.4, 0.6, 0.8 and 1.2 mg/kg  was administered intravenously every other week for 16 weeks. Results demonstrated a median decline in CD4, CD8 and NK cell numbers from baseline of 98, 92 and 79%, respectively and no dose-limiting toxicities were observed. Two patients have completed the protocol and three had partial response. Pharmacokinetic data showed a mean half-life of 32 to 64 h up to the 0.8-mg/kg dose and a lower Cmax value in males. The study was amended to allow for treatment of CMV antigenemia and an intra-patient dose escalation to 2.4, 3.4 and 4.8 mg/kg [&lt;ulink linkID="603447" linkType="Reference"&gt;603447&lt;/ulink&gt;]. In December 2005, further results were presented at the 47th ASH meeting in Atlanta, GA, by which time 16 patients had been enrolled. The median decrease in CD4, CD8, NK and malignant cell numbers in peripheral blood from baseline were 98, 93, 89 and 88%, respectively. At that time, three confirmed partial responses had been observed, six patients had stable disease, and seven patients had progressive disease, four of whom had died during the 1-year follow-up. The drug was well tolerated, but one patient had discontinued therapy due to drug-related polymyalgia rheumatica; three patients were removed due to CMV antigenemia. At that time, enrollment continued [&lt;ulink linkID="641764" linkType="Reference"&gt;641764&lt;/ulink&gt;].  In December 2006, similar data were reported at the 48th ASH meeting in Orlando, FL [&lt;ulink linkID="750664" linkType="Reference"&gt;750664&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, data on siplizumab were published in Blood. Immune deficient mice were infected with adult T-cell leukemia cells and then randomized into three groups, receiving either 4-weekly treatments with siplizumab, 6 months of weekly treatments with siplizumab or no treatment. A fourth group of healthy mice served as a control for survival rate. Results demonstrated that the mice treated with siplizumab for 4 weeks survived longer than infected mice that did not receive treatment and that the 6-month course of therapy significantly improved survival compared to the short-term therapy. In addition, treatment with siplizumab for 6 months led to long-term survival comparable to the survival rate of the healthy mice [&lt;ulink linkID="494569" linkType="reference"&gt;494569&lt;/ulink&gt;], [&lt;ulink linkID="494527" linkType="reference"&gt;494527&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, clinical data on siplizumab were presented at the 44th ASH meeting in Philadelphia, PA. A total of 18 patients with refractory non-Hodgkin's lymphoma (NHL) were treated with 0.5 to 1 mg/kg of siplizumab plus cyclophosphamide with or without thymic irradiation. Siplizumab was detected in patients after 28 days and infusion grade 3 and 4 toxicities were reported. A total of 11 patients showed over 25% regression with four complete responses. Siplizumab had a half-life of 14 days [&lt;ulink linkID="473418" linkType="reference"&gt;473418&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2002, preclinical data on siplizumab were presented at the 44th ASH meeting in Philadelphia, PA. The agent at 100 microg iv was evaluated in NOD/SCID mouse model of adult T-cell leukemia for 6 months. There was a significant prolongation of survival in the treated mice [&lt;ulink linkID="473839" linkType="reference"&gt;473839&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, data from patients with hematological malignancies were presented at the 43rd ASH meeting in Orlando, FL. Of the 20 patients with refractory large B-cell lymphoma treated with siplizumab prior to BMT (ten matched donors, ten mismatched donors), eight achieved a response and five remained alive and progression-free up to 4 years. In further studies, 69 patients with a variety of refractory hematologic malignancies were transplanted using the same regimen, with 46 from matched donors and 23 from mismatched donors. Out of all the patients who maintained long-term full or partial donor chimerism, 35% achieved a complete antitumor response or complete remission. Even among the 20 patients who subsequently lost chimerism, four patients, all with refractory NHL, developed complete antitumor responses. Two of these patients relapsed at 6 and 8 months post-transplant while the other two remained in complete remission more than 2 years after the transplant [&lt;ulink linkID="432979" linkType="reference"&gt;432979&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PSORIASIS&lt;/subtitle&gt;Phase II trials in psoriasis began dosing in April 2001, in North America, and in June 2001, in Europe; at this time, the company was expecting its phase II program to be completed by the end of 2001 [&lt;ulink linkID="403784" linkType="reference"&gt;403784&lt;/ulink&gt;], [&lt;ulink linkID="412009" linkType="reference"&gt;412009&lt;/ulink&gt;]. Enrollment was finally completed in December 2001, with the phase II trial program having accrued 420 psoriasis patients. At this time, dosing was expected to be completed during the first quarter of 2002 [&lt;ulink linkID="434498" linkType="reference"&gt;434498&lt;/ulink&gt;]. In September 2001, assuming continued favorable phase II data, phase III trials were expected to commence in early 2002 [&lt;ulink linkID="422370" linkType="reference"&gt;422370&lt;/ulink&gt;]. In June 2002, phase III trials were expected to begin by year-end 2002 [&lt;ulink linkID="455268" linkType="reference"&gt;455268&lt;/ulink&gt;]. However, in April 2004, the indication was no longer mentioned as part of MedImmune's pipeline [&lt;ulink linkID="536761" linkType="Reference"&gt;536761&lt;/ulink&gt;]. In May 2002, MedImmune planned to initiate a phase II trial in psoriatic arthritis in the second quarter of the year [&lt;ulink linkID="450914" linkType="reference"&gt;450914&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2001, MedImmune commenced a 400-patient phase II study at 50 sites in the US and Canada. The study was a randomized, double-blind, placebo-controlled trial of plaque psoriasis patients receiving siplizumab by sc injection [&lt;ulink linkID="422370" linkType="reference"&gt;422370&lt;/ulink&gt;]. In May 2002, results from the trial were expected in the third quarter of 2002 [&lt;ulink linkID="450914" linkType="reference"&gt;450914&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, MedImmune began its second randomized and double-blind phase II trial, to be conducted at 20 sites in Europe. Approximately 120 patients who had plaque psoriasis involving at least 10% body surface area and a minimum PASI (Psoriasis Area and Severity Index) score of 8 were to be enrolled to receive weekly sc injections of siplizumab. The study was to evaluate both the potential of siplizumab to affect the psoriatic disease of these patients, as measured by PASI score, and the side-effect profile of the drug [&lt;ulink linkID="412009" linkType="reference"&gt;412009&lt;/ulink&gt;]. By September 2001, enrollment of 121 patients was complete in the European study [&lt;ulink linkID="422370" linkType="reference"&gt;422370&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2001, the randomized, double-blind, placebo-controlled phase II trial was being conducted at 25 sites in the US and Canada. Approximately 120 patients with plaque psoriasis involving at least 10% body surface area had been enrolled and were being dosed iv. Dosing of 124 patients was completed in September 2001. The study was to evaluate the potential of siplizumab on psoriatic disease of the patients as well as the side-effect profile of the drug. Two additional phase II trials were planned for later in 2001 [&lt;ulink linkID="403784" linkType="reference"&gt;403784&lt;/ulink&gt;], [&lt;ulink linkID="412009" linkType="reference"&gt;412009&lt;/ulink&gt;], [&lt;ulink linkID="422370" linkType="reference"&gt;422370&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;MedImmune and BioTransplant presented initial clinical data for siplizumab as a potential psoriasis treatment at the International Psoriasis Symposium in San Francisco, CA, during June 2001. Altogether, a phase I, open-label, single-dose iv safety study involving 14 moderate-to-severe psoriasis patients; a phase I/II, open-label, dose-escalation study involving 26 moderate-to-severe psoriasis patients who received up to 8 weekly iv infusions of siplizumab and, a phase I/II, open-label, dose-escalation study involving 39 moderate-to-severe psoriasis patients who received up to 12 weekly sc injections of siplizumab, were reported on. Dosing ranged from 0.0004 mg/kg to 0.04 mg/kg in the iv studies and 0.1 mg to 7.0 mg in the sc study. In all three studies, siplizumab was found to be generally safe and well tolerated. Side effects were considered mild and most commonly included chills and headache in the iv studies, and minimal injection site reaction, chills, and headache in the sc study. Reductions in targeted lymphocyte populations were dose-dependent and less significant when siplizumab was administered sc. Improvement in psoriasis, as measured by PASI score, was observed in all dose groups studied and was most notable among patients at the highest dose levels. Overall, more than 70% of all patients treated experienced at least 25% improvement in PASI score. At the highest dose groups (0.04 mg/kg in the iv studies or 5.0 mg and 7.0 mg in the sc study) more than 55% of patients experienced at least a 50% improvement, while more than 33% showed at least a 75% improvement in their disease [&lt;ulink linkID="413365" linkType="reference"&gt;413365&lt;/ulink&gt;]. This data were also presented at the meeting of the European Society of Dermatological Research, held in Stockholm, Sweden, in September 2001 [&lt;ulink linkID="422897" linkType="reference"&gt;422897&lt;/ulink&gt;]. Data from the phase I program of siplizumab were also presented in February 2002 at the American Academy of Dermatology meeting in New Orleans, LA [&lt;ulink linkID="462301" linkType="reference"&gt;462301&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase I trials had commenced in psoriasis by June 1998 [&lt;ulink linkID="296831" linkType="reference"&gt;296831&lt;/ulink&gt;]. In July 2001, MedImmune began dosing in an open-label, five-arm, single-dose, phase I trial in the US. A total of 25 patients with plaque psoriasis involving at least 10% of body surface area were enrolled to receive single iv or sc doses of siplizumab [&lt;ulink linkID="416851" linkType="reference"&gt;416851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;GvHD&lt;/subtitle&gt;In May 2000, preliminary results of a study using siplizumab as part of BioTransplant's &lt;ulink linkID="20120" linkType="Drug"&gt;AlloMune&lt;/ulink&gt; system were presented at Transplant 2000 in Chicago, IL. In the trial, six patients with blood or bone marrow cancers received mismatched bone marrow transplants. Treatment with the &lt;ulink linkID="20120" linkType="Drug"&gt;AlloMune&lt;/ulink&gt; system, incorporating siplizumab, led to the establishment of a partially blended immune system with no GvHD in four patients. However, by January 2003, the indication was no longer mentioned as part of MedImmune's pipeline for the drug [&lt;ulink linkID="487186" linkType="Reference"&gt;487186&lt;/ulink&gt;]. The company was commencing enrollment in  initial multicenter phase I/II trials in May 2000 [&lt;ulink linkID="366525" linkType="reference"&gt;366525&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1999, results showed that in 17 patients with severe GvHD, siplizumab resulted in improvements in the GvHD grade for a majority of these patients, but 12 out of the 17 died within the 100-day monitoring period as a result of their disease. The company has commenced a new trial in steroid naive GvHD patients [&lt;ulink linkID="331769" linkType="reference"&gt;331769&lt;/ulink&gt;] and an additional study in children with GvHD for whom there are no approved therapies. The results of these two trials and the phase I trial of patients with psoriasis were expected to be available by the end of 1999 [&lt;ulink linkID="333478" linkType="reference"&gt;333478&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 1999, results of a phase I/II trial that were presented at the 28th Annual Meeting of the International Society for Experimental Hematology. These data indicated that siplizumab provided potential clinical benefit for treatment of steroid-resistant GvHD [&lt;ulink linkID="335691" linkType="reference"&gt;335691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Additional phase I/II trials for GvHD were initiated in December 1998; the first was to be conducted as a placebo-controlled adult steroid-naive bone marrow transplant (BMT) or stem cell transplant (SCT) recipients who would receive siplizumab combined with corticosteroids. It was anticipated the trial would include 32 patients at up to 15 US centers. The second study was to be an open label trial to assess siplizumab for its ability to treat GvHD in pediatric BMT or SCT patients. Up to 20 patients were expected to be recruited, aged 2 to 17 [&lt;ulink linkID="309251" linkType="reference"&gt;309251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2000, data from a phase I dose escalation trial were presented at the 42nd Annual Meeting of the American Society of Hematology in San Francisco, CA. The safety and tolerance of siplizumab was evaluated in 34 patients with acute grade 2 GvHD, randomized to receive 0.012, 0.04, 0.12 or 0.4 mg/kg siplizumab, or saline placebo. Adverse events were similar in the siplizumab and placebo groups. Antibodies to siplizumab were not detected in any patient, and all patients were treated with therapeutic steroid doses. Of the 21 siplizumab patients, 14 (67%) achieved grade 0 GvHD during 100 days of follow-up, compared to 7 (54%) in the placebo group who received steroids alone. The treatment was well tolerated and was not associated with increased toxicity [&lt;ulink linkID="394133" linkType="reference"&gt;394133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 1998, the results of a phase I safety and pharmacokinetic study were presented at the 24th Annual Scientific Meeting of the American Society for Transplant Surgeons in Chicago, IL. The phase I study was a open-label, dose-escalating safety trial, in renal allograft patients, evaluating three dose levels (0.012, 0.06 and 0.12 mg/kg/dose). A total of 13 patients were given an initial dose within 6 h after kidney transplant and a second dose 60 to 72 h later. The antibody was well tolerated and no anti-siplizumab antibodies were detected following administration. However, during a 30-day follow-up, two patients experienced acute rejection [&lt;ulink linkID="287243" linkType="reference"&gt;287243&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2006, preclinical data on siplizumab were presented at the 48th ASH meeting in Orlando, FL. Siplizumab was found to induce apoptosis of malignant T cells in a dose-dependent manner. Intravenous administration in transgenic mice caused a reduction in the number of peripheral huCD2+ T cells but the number of CD19+ B cells was unchanged [&lt;ulink linkID="750234" linkType="Reference"&gt;750234&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2003, following filed voluntary petitions for reorganization under Chapter 11 of the US Bankruptcy Code [&lt;ulink linkID="480211" linkType="reference"&gt;480211&lt;/ulink&gt;], BioTransplant had reported that it had no active operations [&lt;ulink linkID="514608" linkType="reference"&gt;514608&lt;/ulink&gt;] and involvement in the antibody program was assumed to have been discontinued by that time.&lt;/para&gt;&lt;para&gt;In September 2001, US Bancorp Piper Jaffray predicted product launch in 2004 with a peak sales potential of $250 million for psoriasis [&lt;ulink linkID="426943" linkType="reference"&gt;426943&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1998, the USPTO issued &lt;ulink linkID="IN2687991" linkType="Patent"&gt;US-05817311&lt;/ulink&gt; to BioTransplant. The patent, sublicensed to MedImmune, relates to BTI-322 and its humanized form, MEDI-507, and covers the use of any antibody binding to the target epitope recognized by BTI-322 and MEDI-507 [&lt;ulink linkID="300856" linkType="reference"&gt;300856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1995, BioTransplant and MedImmune entered into a strategic collaboration to develop and commercialize &lt;ulink linkID="9071" linkType="Drug"&gt;MEDI-500&lt;/ulink&gt;, &lt;ulink linkID="8711" linkType="Drug"&gt;BTI-322&lt;/ulink&gt; and any future generation products derived from either of these drugs. MedImmune was to  undertake responsibilty and funding of clinical trials and commercialization. BioTransplant would receive license fees, research support and  milestones, as well as royalties on  product sales  [&lt;ulink linkID="189920" linkType="Reference"&gt;189920&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In 1993, Universite Catholique de Louvain and BioTransplant entered into a research and licensing agreement, in which BioTransplant gained exclusive rights to BTI-322 [&lt;ulink linkID="477585" linkType="Reference"&gt;477585&lt;/ulink&gt;]. In January 2003, UCL notified BioTransplant  that it intended to terminate the agreement  and regain rights and licenses from BioTransplant as UCL had asserted that BioTransplant had breached the agreement [&lt;ulink linkID="477585" linkType="reference"&gt;477585&lt;/ulink&gt;]. Later the same month, UCL agreed to suspend its notice of termination for 30 days, in an attempt to resolve the alledged breached agreement claim [&lt;ulink linkID="477784" linkType="reference"&gt;477784&lt;/ulink&gt;]. In April 2003, a settlement agreement was reached, where BioTransplant retained all exclusive rights to BTI-322 [&lt;ulink linkID="484442" linkType="Reference"&gt;484442&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Siplizumab is a humanized IgG1 monoclonal antibody that binds to CD2 surface antigen receptors, found on T-cells and natural killer cells [&lt;ulink linkID="270316" linkType="reference"&gt;270316&lt;/ulink&gt;], [&lt;ulink linkID="416847" linkType="reference"&gt;416847&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1158077">ITB-MED AB</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3004">Organ transplantation</Indication><StatusDate>2017-09-07T00:00:00.000Z</StatusDate><Source id="1965438" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="203">Lymphoma</Indication><StatusDate>2007-07-26T00:00:00.000Z</StatusDate><Source id="816181" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="616">Graft versus host disease</Indication><StatusDate>2003-11-24T00:00:00.000Z</StatusDate><Source id="514608" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="36">Autoimmune disease</Indication><StatusDate>2003-11-24T00:00:00.000Z</StatusDate><Source id="514608" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14847">BioTransplant Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2003-11-24T00:00:00.000Z</StatusDate><Source id="514608" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate>2003-11-24T00:00:00.000Z</StatusDate><Source id="514608" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="199">Leukemia</Indication><StatusDate>2007-07-26T00:00:00.000Z</StatusDate><Source id="816181" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="515">Transplant rejection</Indication><StatusDate>2003-11-24T00:00:00.000Z</StatusDate><Source id="514608" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate>2003-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2004-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2004-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2004-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2004-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>2001-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2004-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21279">Universite Catholique de Louvain</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>1993-12-31T00:00:00.000Z</StatusDate><Source id="477585" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2001-06-01T00:00:00.000Z</StatusDate><Source id="412009" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2001-04-01T00:00:00.000Z</StatusDate><Source id="403784" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><Source id="283196" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><Source id="283196" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>1997-11-26T00:00:00.000Z</StatusDate><Source id="270316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>1997-11-26T00:00:00.000Z</StatusDate><Source id="270316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1997-11-26T00:00:00.000Z</StatusDate><Source id="270316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1998-03-19T00:00:00.000Z</StatusDate><Source id="281528" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1998-03-19T00:00:00.000Z</StatusDate><Source id="281528" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>1996-12-19T00:00:00.000Z</StatusDate><Source id="228865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14847">BioTransplant Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1996-12-19T00:00:00.000Z</StatusDate><Source id="228865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>1996-12-19T16:37:41.000Z</StatusDate><Source id="228865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1996-12-19T16:37:41.000Z</StatusDate><Source id="228865" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>1997-11-26T00:00:00.000Z</StatusDate><Source id="270316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1997-11-26T00:00:00.000Z</StatusDate><Source id="270316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1998-03-19T00:00:00.000Z</StatusDate><Source id="281528" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><Source id="283196" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><Source id="283196" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2001-06-01T00:00:00.000Z</StatusDate><Source id="412009" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2001-04-01T00:00:00.000Z</StatusDate><Source id="403784" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2001-10-01T00:00:00.000Z</StatusDate><Source id="422370" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2002-05-13T00:00:00.000Z</StatusDate><Source id="450914" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="515">Transplant rejection</Indication><StatusDate>1998-03-19T00:00:00.000Z</StatusDate><Source id="281528" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate>1998-11-26T00:00:00.000Z</StatusDate><Source id="307125" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>1997-11-26T00:00:00.000Z</StatusDate><Source id="270316" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2005-05-17T00:00:00.000Z</StatusDate><Source id="601766" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate>2005-05-17T00:00:00.000Z</StatusDate><Source id="601766" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1158077">ITB-MED AB</OwnerCompany><Country id="US">US</Country><Indication id="3004">Organ transplantation</Indication><AwardedIndication>Prevention of solid organ transplant rejection</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-02-15T00:00:00.000Z</MileStoneDate><Source id="2006775" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1158077">ITB-MED AB</OwnerCompany><Country id="EU">EU</Country><Indication id="3004">Organ transplantation</Indication><AwardedIndication>Treatment in solid organ transplantation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-10-16T00:00:00.000Z</MileStoneDate><Source id="1987727" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1158077">ITB-MED AB</OwnerCompany><Country id="EU">EU</Country><Indication id="3004">Organ transplantation</Indication><AwardedIndication>Treatment in solid organ transplantation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2017-09-07T00:00:00.000Z</MileStoneDate><Source id="1965438" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18008">MedImmune LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="203">Lymphoma</Indication><AwardedIndication>Treatment of T-cell and NK-cell neoplasms</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2006-06-29T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18008">MedImmune LLC</OwnerCompany><Country id="EU">EU</Country><Indication id="203">Lymphoma</Indication><AwardedIndication>Treatment of T-cell and NK-cell neoplasms</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2006-05-16T00:00:00.000Z</MileStoneDate><Source id="668386" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18008">MedImmune LLC</OwnerCompany><Country id="US">US</Country><Indication id="203">Lymphoma</Indication><AwardedIndication>Treatment of T-cell lymphomas</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2003-07-15T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="18008">MedImmune LLC</OwnerCompany><Country id="US">US</Country><Indication id="616">Graft versus host disease</Indication><AwardedIndication>Treatment of graft-versus-host disease.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1998-11-13T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14847">BioTransplant Inc</OwnerCompany><Country id="US">US</Country><Indication id="515">Transplant rejection</Indication><AwardedIndication>For the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.</AwardedIndication><DesignationType id="2">Prevention</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1998-09-17T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00364"><Name>Lymphocyte function antigen-3 receptor</Name><SwissprotNumbers><Swissprot>P06729</Swissprot><Swissprot>P08920</Swissprot><Swissprot>P08921</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1158077">ITB-MED AB</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="14847">BioTransplant Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18592">BioInvent International AB</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19162">PDL BioPharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="122289" title="MedImmune to develop BioTransplant's BTI-322, siplizumab and other organ rejection drugs   "/><Deal id="238679" title="Humanized antibody for CD-2 (MEDI-507) "/><Deal id="245149" title="ITB-MED to acquire AstraZeneca's siplizumab assets for treatment of organ transplantation"/><Deal id="251232" title="BioInvent to perform cGMP manufacturing of ITBMed's siplizumab for solid organ transplantation"/></Deals><PatentFamilies><PatentFamily id="1460215" number="WO-09420619" title="LO-CD2a antibody and uses thereof for inhibiting T-cell activation and proliferation."/><PatentFamily id="1753474" number="WO-2005003302" title="Novel methods to modulate mast cells"/><PatentFamily id="2028822" number="WO-2004022097" title="Methods of preventing or treating cell malignancies by administering cd2 antagonists"/><PatentFamily id="4475460" number="WO-2019075125" title="Compositions and methods for using the CD2-based signaling pathways to block HIV infection"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioTransplant Inc" id="14847"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universite Catholique de Louvain" id="21279"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="George Mason University" id="31512"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>